Business intelligence reports for the lab diagnostics industry
Subscribe for Exclusive Access.
Subscriptions & Reports
![Mar2022-DTET-Cover](https://g2woo.wpengine.com/wp-content/uploads/2022/03/Mar2022-DTET-Cover.webp)
![March2022-LCA.Cover](https://g2woo.wpengine.com/wp-content/uploads/2022/03/March2022-LCA.Cover_.webp)
![March2022-LIR-Cover](https://g2woo.wpengine.com/wp-content/uploads/2022/03/March2022-LIR-Cover.webp)
![April-2022-NLR-Briefing-Cover](https://g2woo.wpengine.com/wp-content/uploads/2022/03/April-2022-NLR-Briefing-Cover.webp)
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
Exosome Prostate Cancer Test Does Well in Clinical Validation Study
By Ron Shinkman, Editor, Laboratory Industry Report Massachusetts-based Exosome Diagnostics has released data from a clinical validation study suggesting its liquid biopsy test for prostate cancer patients could more accurately predict the presence of the disease...
Sequencing to Target Pancreatic Cancer Tx ‘Challenging’ in Real World
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Real-world application of sequencing for targeting pancreatic cancer treatment remains challenging, according to a study published in Clinical Cancer Research and presented at the American...
FDA Approves Roche’s KRAS Mutation Test
By Stephanie Murg, Managing Director, G2 Intelligence Roche's portfolio of companion diagnostics now includes a test that can help clinicians to tailor treatment for patients with metastatic colorectal cancer. The U.S. Food and Drug Administration has approved the...
Technology Connects Lab-Discarded Specimens with Researchers; Provides Labs New Revenue
By Kelly A. Briganti, Editorial Director, G2 Intelligence Technology is making use of hospital and laboratory specimens that would otherwise be discarded by connecting those specimen sources with biomedical researchers. iSpecimen (Lexington, Mass.), founded in...